Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment
Status:
Terminated
Trial end date:
2019-04-08
Target enrollment:
Participant gender:
Summary
To characterize the pharmacokinetics and safety of dabrafenib following a single 100 mg oral
dose in subjects with moderate and severe hepatic impairment.